Skip to main content
Delfa

← All trials/NCT05285397

UnknownPhase NA

Effect of Liraglutide on Weight Loss in Patients Who Have Undergone Revisional Bariatric Surgeries.

Liraglutide's Effect on Weight Loss in Patients After Secondary Bariatric Surgery ; a Randomized Double-blind Controlled Study.

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

-

Estimated enrollment

60

Study population

Bariatric Surgery, Obesity / overweight

Eligibility highlights

•BMI ≥35

Primary endpoints

•Body weight, % change•Percentage Excess body weight loss

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT05285397
Org study IDLiraglutide1

Timeline

Milestones

Study start2022-03-10estimated
Study first posted2022-03-17actual
Last update posted2022-03-17actual
Primary completion2022-09estimated (month precision)
Study completion2022-09estimated (month precision)

Assets

Investigational agents

Liraglutide

Who this study enrolls

Bariatric SurgeryObesity / overweight

Who can enroll

SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Undergone primary bariatric surgery
•Need secondary bariatric surgery due to either weight regain (regained weight to have BMI > 35) or medical associated diseases

Exclusion criteria

•Prior use of GLP-1 agonist
•Past history of pancreatitis
•Personal or family history of medullary thyroid cancer
•Pregnancy or lactation
•Acute coronary syndrome
•Hepatic or renal dysfunction
•Active malignancy

Endpoints (12)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition
4
Glycemic / diabetes
4
Cardiometabolic biomarkers
2
Other clinical outcomes
1
Other (unclassified)
1

Weight & body composition

4 endpoints
Primary/protocol endpoint

Percentage Total weight loss

Time frame:6 months

Body weight, % change

percent change from baseline, improvement

Primary/protocol endpoint

Percentage Excess body weight loss

Time frame:6 months

percent change from baseline, improvement

Secondary/protocol endpoint

Weight

Time frame:6 months

descriptive, improvement

Secondary/protocol endpoint

BMI

Time frame:6 months

BMI, change

change from baseline, improvement

Glycemic / diabetes

4 endpoints
Secondary/protocol endpoint

HbA1C

Time frame:6 months

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Secondary/protocol endpoint

Fasting Blood Glucose (FBG)

Time frame:6 months

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Secondary/protocol endpoint

HOMA-IR

Time frame:6 months

HOMA-IR (insulin sensitivity)

change from baseline, improvement

Secondary/protocol endpoint

Resolution of type 2 Diabetes Mellitus

Time frame:6 months

categorical status, improvement

Cardiometabolic biomarkers

2 endpoints
Secondary/protocol endpoint

Blood pressure

Time frame:6 months

change from baseline, improvement

Secondary/protocol endpoint

Lipid profile

Time frame:6 months

change from baseline, improvement

Other clinical outcomes

1 endpoint
Secondary/protocol endpoint/low confidence

Sleep apnea

Time frame:6 months

descriptive, improvement

Other (unclassified)

1 endpoint
Secondary/protocol endpoint/low confidence

Comorbidities

Time frame:6 months

descriptive

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 6, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.